Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR S768I

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

therascreen® EGFR RGQ PCR Kit (5)

therascreen® EGFR RGQ PCR Kit (5)

EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR S768I	Lung Adenocarcinoma	EGFR S768I	Lung Adenocarcinoma	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR S768I	Lung Adenocarcinoma	EGFR S768I	Lung Adenocarcinoma	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4
EGFR S768I	Lung Adenocarcinoma	EGFR S768I	Lung Adenocarcinoma	bevacizumab + afatinib Sensitive: C4 – Case Studies bevacizumab + afatinib Sensitive : C4	bevacizumab + afatinib Sensitive: C4 – Case Studies bevacizumab + afatinib Sensitive : C4